Cuprimine Related Published Studies
Well-designed clinical trials related to Cuprimine (Penicillamine)
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.09]
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.04.16]
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. [2004.02]
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. [2001.03]
D-penicillamine is not an effective treatment in systemic sclerosis. [2001]
Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. [2000.11]
Penicillamine in the treatment of systemic sclerosis. [1999.10]
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. [1999.06]
Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. [1998.10]
A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. [1998.09]
A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. [1997]
D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. [1996.11]
Long term survival in Indian childhood cirrhosis treated with D-penicillamine. [1996.01]
Reversal of Indian childhood cirrhosis by D-penicillamine therapy. [1995.01]
Penicillamine in rheumatoid arthritis. A problem of toxicity. [1992.01]
Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study. [1992]
Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. [1991.06]
Toward a rational therapeutic strategy for arachnoiditis. A possible role for d-penicillamine. [1991.02]
A study of adjunctive copper sulphate treatment in patients with rheumatoid arthritis who have relapsed while taking D-penicillamine. [1991.01]
Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. [1990.04]
OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study. [1990]
Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. [1989]
Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. [1988.11]
Prospective trial of penicillamine in primary sclerosing cholangitis. [1988.10]
Clinical trials of penicillamine in Indian childhood cirrhosis. [1987.11]
Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. [1987.10]
Well-designed clinical trials possibly related to Cuprimine (Penicillamine)
Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. [2010.05]
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. [2009.08]
Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. [2009.05.01]
Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20. [2004.05]
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. [2004.04]
The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis. [2003.01]
Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. [2001.09]
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. [2000.06]
The Fifth Carlos E. Rubio Memorial Lecture. Sclerosing cholangitis: pathogenesis, pathology, and practice. [1999.03]
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. [1999.03]
Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. [1997.05]
Time course of histological progression in primary biliary cirrhosis. [1996.01]
[A prospective study of plasma exchange in the treatment of diffuse scleroderma] [1995.09]
Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis. [1994.12]
Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. [1993.08]
[A comparative controlled trial of 2 administration modalities of tiopronin in rheumatoid arthritis] [1993.05]
Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. [1992.03]
Cholangiocarcinoma complicating primary sclerosing cholangitis. [1991.01]
Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. [1990.08.04]
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. [1990.04]
Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. [1990.01]
Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. [1988.01]
Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. [1985.11]
Other research related to Cuprimine (Penicillamine)
Evaluation of Cuprimine(R) and Syprine(R) for decorporation of radioisotopes of cesium, cobalt, iridium and strontium. [2011.08]
D-penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluator-blinded, vehicle-controlled, in vivo study. [2011.06]
D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. [2011.04.15]
Involvement of T helper 17 cells in D-penicillamine-induced autoimmune disease in Brown Norway rats. [2011.04]
Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation. [2011.04]
Administration of a novel penicillamine-bound membrane: a preventive and therapeutic treatment for abdominal adhesions. [2011.02.25]
Combination therapy with andrographolide and d-penicillamine enhanced therapeutic advantage over monotherapy with d-penicillamine in attenuating fibrogenic response and cell death in the periportal zone of liver in rats during copper toxicosis. [2011.01.01]
Penicillamine-induced elastosis perforans serpiginosa with abnormal "lumpy-bumpy" elastic fibers in lesional and non-lesional skin. [2011.01]
Systemic administration of D-penicillamine prevents the locomotor activation after intra-VTA ethanol administration in rats. [2010.10.11]
Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease. [2010.09]
Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report. [2010.08]
Intracellular delivery of the reactive oxygen species generating agent D-penicillamine upon conjugation to poly-L-glutamic acid. [2010.06.07]
Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine. [2010.05]
Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po. [2010.03]
Copper and zinc in the serum, urine, and hair of patients with Wilson's disease treated with penicillamine and zinc. [2010.03]
Penicillamine as a potent protector against injurious effects of cigarette smoke in aerodigestive tract cancer. [2010]
Penicillamine-induced elastosis of the mucosal lip. [2009.04]
Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. [2009]
Treatment of periocular hyperpigmentation due to lead of kohl (surma) by penicillamine: a single group non-randomized clinical trial. [2009]
Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease. [2008.12]
Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. [2008.12]
Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease. [2008.12]
A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.05]
A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.02.16]
Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy. [2008.02]
Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. [2008.01.15]
Effect of penicillamine and zinc on iron metabolism in Wilson's disease. [2007.12]
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. [2007.11]
Effect of oral D-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.10]
Effect of oral d-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.06.05]
D-Penicillamine administration and the incidence of retinopathy of prematurity. [2007.02]
Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease. [2007.02]
Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. [2007.02]
Liquid chromatography/tandem mass spectrometry determination of (4S,2RS)-2,5,5-trimethylthiazolidine-4-carboxylic acid, a stable adduct formed between D-(-)-penicillamine and acetaldehyde (main biological metabolite of ethanol), in plasma, liver and brain rat tissues. [2007]
Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis--Cochrane Hepato-Biliary Group. [2006.12]
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. [2006.10]
Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit. [2006.08]
Voluntary ethanol consumption decreases after the inactivation of central acetaldehyde by d-penicillamine. [2006.07.15]
Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. [2006.06.05]
Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit. [2006.02.15]
A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. [2006.02]
[Penicillamine-induced bronchiolitis obliterans diagnosed by transbronchial lung biopsy] [2006.02]
D-penicillamine for primary sclerosing cholangitis. [2006.01.25]
Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. [2006]
Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. [2005.08]
Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa. [2005.07]
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. [2005.07]
D-Penicillamine improved laparoscopic and histological findings of the liver in a patient with Wilson's disease: 3-year follow-up after diagnosis of Coombs-negative hemolytic anemia of Wilson's disease. [2005.06]
Penicillamine induced pseudoxanthoma elasticum with elastosis perforans serpiginosa. [2005.05]
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. [2005.02]
Improvement in liver pathology after 4 months of D-penicillamine in 5 doberman pinschers with subclinical hepatitis. [2005.01]
Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus. [2005.01]
|
